Abstract: Crystalline complexes of steroid hormones with gamma-cyclodextrin are prepared by mixing the components together. Tablets can be formed from the complexes, which can be administered by contact with the mucosa to provide effective transfer of the hormones into the systemic circulation, gradually eliminating the hormones therefrom.

Abstract: A preparation containing an absorption promoter selected from N-acyl amino acid derivatives or N-acyl peptide derivatives represented by the formula: R-CO-A (R is an aliphatic hydrocarbon group, an aromatic hydrocarbon group or an aryl-substituted lower hydrocarbon group which may optionally be substituted, and A is an amino acid residue or a peptide residue), preferably in the presence of a salt at a concentation exhibiting higher osmotic pressure than isotonic sodium chloride solution, and a medicine is found to promote absorption of the medicine through a gastrointestinal organ such as the colon and rectum, and through the vagina.

Abstract: A percutaneous absorption preparation which comprises calcium salt of an acidic anti-inflammatory or analgesic drug having carboxyl group as the active ingredient and present in an amount of 0.3-10% by weight; a medium for the active ingredient which is selected form the group consisting of an ethylene glycol mono-lower alkyl ether, propylene glycol, polyethylene glycol and dimethylsulfoxide, the medium being present in an amount at least sufficient to dissolve the active ingredient; an absorption promotor selected from the group consisting of 1-dodecylazacycloheptan-2-one, hexamethylenelauramide, N-methyl-2-pyrrolidone, a sucrose aliphatic acid ester, dimethylsulfoxide and a nonionic surfactant and present in an amount of 0.5-10% by weight; and the remaining being other reagents and/or carriers required for a desired form of the preparation.

Abstract: A pharmaceutical composition, comprising: Coenzyme Q.sub.10 (ubidecarenone) 2-17% by weight; Lecithin 50-70% by weight; Surfactant agent 20-48% by weight. The surfactant agent has a melting point comprised between 35.degree. and 55.degree. C. and a HLB value from 12 to 15. Said composition provides a high absorption of Coenzime Q.sub.10. Solid pharmaceutical preparations containing the above composition are described too.

Abstract: A percutaneous absorption accelerator and a precutaneous absorbent preparation containing the same and, more particularly, a percutaneous absorption accelerator containing ether derivatives of specific glycerols or polyglycerols and alcohols as effective components and a percutaneous absorbent preparation containing the percutaneous absorption accelerators and pharmaceutically effective components.

Abstract: A pharmaceutical composition comprises a benzoyl urea compound having the formula: ##STR1## wherein X is a nitro group, Y is a chlorine atom, Z.sub.2 is a hydrogen atom, Z.sub.1 is a halogen atom, and A is a nitrogen atom, and at least one member selected from the group consisting of a cyclodextrin, a polyethylene glycol and a refined oil.

Abstract: Acylcarnitine used as a nasal, buccal, sublingual and vaginal drug absorption enhancing vehicle for poorly absorbed drugs.

Abstract: Polyprenyl alcohol-containing injections comprising polyprenyl alcohols shown by the formula: ##STR1## wherein n is an integer of 5 to 7, and lecithin as essential ingredients. The subject injections can enhance utilization of the polyprenyl alcohols contained therein in vivo, thereby effectively preventing or treating infectious diseases in humans or animals.

Abstract: Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities.

Abstract: Compositions for the transdermal delivery of azatadine and the use of such compositions in the treatment of allergic reactions are disclosed.

Abstract: This invention provides a method of combating termites at a locus, which comprises treating the locus e.g. soil or timber with an acyl urea of the formula ##STR1## wherein one substituent X is a halogen atom or a merthyl group and the other is a halogen atom, a hydrogen atom or a methyl group, and each of R.sup.1, R.sup.2 and R.sup.3 independently represents a hydrogen or fluorine atom; the use of acyl ureas of formula I for combating termites; and compositions for protecting timber against termite attack.

Abstract: The transdermal penetration of N-(2-hydroxyethyl) nicotinamide nitrate useful for the treatment of angina pectoris is improved by the use of a mixed solvent comprising an alcohol of 2 to 7 carbon atoms and an aliphatic ester having a molecular weight of at least 180 in the formulation of the external preparations.

Abstract: Choline ester salts are used as drug absorption enhancing agents for orally and rectally administered drugs.

Abstract: Cosmetic Base composition exhibiting therapeutic properties includes an acyl fatty acid lactylate ester or alkali metal salt thereof, a sucrose fatty acid ester, and a solvent.

Abstract: A dilutant for industrial herbicides applied to non-agricultural areas is disclosed in which a combination of a hydrocarbon filler, lecithin, and a mixture of other chemicals creates a dilutant with a strong affinity for emulsifiable and oil-soluble industrial herbicides, insecticides, and fungicides, and which dilutant is capable of penetrating tree bark and woody plant tissue while retaining the active ingredients and allowing the active ingredients to move upward within the xylem of the plant and downward within the phloem of the plant.

Abstract: A dosage form that coadministers a drug and two percutaneous absorption enhancers to a defined area of the skin is described. The dosage form comprises a body that contains supplies of drug and enhancers and has a basal surface that contacts the area of skin and transmits the drug and enhancers to the area for absorption thereby.

Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula ##STR1## wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of alkyl radicals and cycloalkyl radicals comprising from 1 to 20 carbon atoms and R is selected from the group consisting of alkyl radicals and cycloalkyl radicals comprising from 1 to 30 carbon atoms; provided, however, that the total number of carbon atoms in said compound is 15 or more and the total number of carbon atoms in R.sup.1 and R.sup.2 is 5 or more.

Abstract: A method, composition, and article for use in transdermal or percutaneous administration to humans of systemically active medicaments in the form of a solution in benzyl alcohol.

Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula ##STR1## wherein X and Y, each, may represent sulfur, oxygen or two hydrogen atoms, A is a branched or a straight chain, divalent aliphatic radical having from 0 to 2 double bonds; R' is selected from the group consisting of H, a lower alkyl group having 1-4 carbon atoms, phenyl, lower alkyl or halogen substituted phenyl, acetamido, halogen, piperidinyl, lower alkyl or halogen substituted piperidinyl, carbalkoxy, carboxamide, and alkylformyl; m is 3-7; q is 2m-2x, wherein x equals the number of double bonds in the lactam ring and may be 1, 2 or 3, and R is CH.sub.3, ##STR2## wherein R" is H or halogen.

Abstract: Certain proteolipid humectant macromolecules; method of obtaining by isolating these from tissue of vertebrates or by culturing; use of such proteolipids to treat dry human skin; compositions containing such proteolipids; and method for analysis of proteolipid concentration.

Abstract: A pharmaceutical composition for external use with the enhanced penetration of a pharmacologically active agent through the skin or mucosa of a warm-blooded animal, said composition comprising(A) a pharmaceutically effective amount of the pharmacologically active agent, and(B) an optically active or inactive pyroglutamate of the following formula ##STR1## wherein R represents a linear, branched or cyclic alkyl or alkenyl group having 10 to 14 carbon atoms,as a penentration enhancer.

Abstract: A method of enhancing penetration of a drug through the skin or other biological membranes using lecithin is herein described along with pharmaceutical compositions containing effective amounts of lecithin as a penetration enhancer.

Abstract: A dosage form that coadministers a drug and two percutaneous adsorption enhancers to a defined area of the skin is described. The dosage form comprises a body that contains supplies of drug and enhancers and has a basal surface that contacts the area of skin and transmits the drug and enhancers to the area for absorption thereby.

Abstract: The present invention provides a therapeutic toilet solution effective for the eradication and prevention of skin lesions or warts associated with condylomata acuminata, and a method of dispersion thereof.

Abstract: This invention provides compositions comprising a physiologically-active agent and an azacycloalkene having at least one double bond in the ring and of the general formula ##STR1## wherein X and Y, each, may represent sulfur, oxygen or two hydrogen atoms, A is a straight or branched chain, divalent aliphatic radical having from 0 to 2 double bonds; R' is selected from the group consisting of H, a lower alkyl group having 1-4 carbon atoms, phenyl, lower alkyl or halogen substituted phenyl, acetamido, halogen, piperidinyl, lower alkyl or halogen substituted piperidinyl, carbalkoxy, carboxamide, and alkylformyl; m is 3-7; q is 2m-2x, wherein x equals the number of double bonds in the lactam ring and may be 1, 2 or 3; and R is --CH.sub.3, ##STR2## wherein R" is H or halogen in an amount effective to enhance the penetration of the physiologically-active agent through the skin or other membrane of the body of an animal.

Abstract: A synthetic resin matrix system for the delayed and extended duration delivery of drugs to humans and animals is disclosed consisting of a polymer, such as poly(2-hydroxyethylmethacrylate), referred to as PHEMA, an organic solvent, such as polyethylene glycol (PEG), and a hydrogen binding plasticizer, such as dimethylsulfoxide (DMSO). The plasticizer regulates the set-up time of the synthetic resin so that the more plasticizer present, the shorter the set-up time. The plasticizer also has a direct shortening effect upon the cure time and also profoundly influences many of the physical characteristics of the resultant synthetic resin matrix system. A variety of drugs can be embodied in the fabricated matrix system and administered to the patient (or animal) by different modes of application, including but not limited to oral, topical, rectal, subcutaneous implant, or organ-specific implant such as in the conjunctival sac of the eye.

Abstract: A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with glycerol monolaurate. Preferred embodiments of therapeutic systems for delivering drug and glycerol monolaurate employ matrix containing drug at a concentration above saturation.

Abstract: A pharmaceutical composition for external use with the enhanced penetration of a pharmacologically active agent through the skin or mucosa of a warm-blooded animal, said composition comprising(A) a pharmaceutically effective amount of the pharmacologically active agent such as antiinflammatory agent, etc., and(B) a penetration enhancer of the following formula (1) ##STR1## wherein R.sub.1 and R.sub.2 are identical or different and each represents H, a C.sub.1-25 alkyl, C.sub.2-25 alkenyl, a (C.sub.1-24 alkyl)carbonyl or a (C2-24 alkenyl)carbonyl, provided that R.sub.1 and R.sub.2 are not H at the same time, or R.sub.1 and R.sub.2, taken together, may form a group of the following formula (a) ##STR2## in which R.sub.3 and R.sub.4 are identical or different and each represents H, C.sub.1-24 alkyl or C.sub.1-24 alkenyl.

Abstract: Acylcarnitine used as a nasal, buccal, sublingual and vaginal drug absorption enhancing vehicle for poorly absorbed drugs.

Abstract: Choline ester salts are used as drug absorption enhancing agents for orally and rectally administered drugs.

Abstract: A synthetic resin matrix dressing is disclosed consisting essentially of a polymer, such as poly(2-hydroxyethylmethacrylate), referred to as PHEMA, an organic solvent, such as polyethylene glycol (PEG), and a hydrogen bonding plasticizer, such as dimethylsulfoxide (DMSO). The plasticizer regulates the set-up time of the synthetic resin so that the more plasticizer present, the shorter the set-up time. The dressing may be applied to the treatment site in veterninary use in the form of a paste for the in-situ curing or setting thereof, or the dressing may be preformed and then applied to the treatment site. A variety of drug agents may be incorporated in the synthetic resin matrix so as to result in the time released administration of the drug agent to the area of the skin covered by the dressing. A method of treatment using this dressing is also disclosed.

Abstract: A readily absorbable pharmaceutical composition of pharmacologically active agents, which per se are poorly absorbable, is disclosed which comprises a pharmacologically effective amount of at least one such pharmacologically active agent distributed in a vehicle comprising an absorption-enhancing amount of at least one fatty acid of medium chain length. The preparation is suited for formulating pharmacologically active bases, cardiac glycosides, steroids, antibiotics, sympathicomimetica, tranquilizing agents, or local anaesthetics.

Abstract: Drug preparations for external application having a stick-itself-to-the-skin property, so-called "soft patch", are provided. The preparations contain a drug, a water-soluble protein having an absorption-promoting effect, a polyhydric alcohol a tackifier, and an oleaginous substance, and ensure an improved percutaneous absorption and bioavailability of the drugs, thus permitting an accurate control of drug dosage.

Abstract: Choline esters are used as drug absorption enhancing agents for drugs which are poorly absorbed from the nasal, oral, and vaginal cavities.

Abstract: Compositions are provided comprising a polymer processing aid, and from about 5% to about 20% by weight, based on the total weight of the composition, of a microbiocidal compound, said microbiocidal compound being present as the solute in an aryl alkanol solvent, and the aryl alkanol solvent being present in an amount such that the weight ratio of the aryl alkanol solvent to microbiocidal compound is from about 3/1 to about 5/1.

Abstract: Provided are microbiocidal solutions comprising an aryl alkanol solvent and a microbiocidal compound dissolved therein. The solutions may be used to impart microbiocidal properties to polymer compositions.

Abstract: This invention relates to a fast release solid preparation, which comprises a solid dispersion composition containing dihydropyridien A compound uniformly dispersed in hydroxypropylmethyl cellulose as the dispersion medium, said dihydropyridine A compound being maintained in the amorphous state in said solid dispersion composition.

Abstract: A method for transdermal delivery of naloxone, naltrexone and nalbuphine base through intact skin is described. Preferred embodiments of transdermal therapeutic systems for delivering these drugs and polyethylene glycol monolaurate employ an ethylene vinylacetate matrix containing drug base at a concentration above saturation and polyethylene glycol monolaurate below unit activity. Polyethylene glycol manolaurate is disclosed as a permeation enhancer for the base form of these drugs and is preferably delivered simultaneously with the drug.

Abstract: A method for enhancing the transdermal flux of a transdermally deliverable drug through intact skin is described in which the drug is delivered simultaneously with polyethylene glycol monolaurate. Preferred embodiments of transdermal therapeutic systems for delivering drug and polyethylene glycol monolaurate employ matrix containing drug at a concentration above saturation.

Abstract: A synthetic resin wound dressing (e.g., a burn wound dressing) is disclosed consisting essentially of a polymer, such as poly(2-hydroxyethylmethacrylate), referred to as PHEMA, an organic solvent, such as polyethylene glycol (PEG), and a hydrogen binding plasticizer, such as dimethylsulfoxide (DMSO). The plasticizer regulates the set-up time of the synthetic resin so that the more plasticizer present, the shorter the set-up time. The dressing may be applied to the wound site in the form of a paste for the in situ curing or setting thereof, or the dressing may be preformed and then applied to the wound site. A variety of drug agents (e.g., silver sulfadiazine) may be incorporated in the synthetic resin so as to result in the time released administration of the drug agent to the area of the skin (e.g., a burn wound site or the like) covered by the wound dressing. A method of treatment using this dressing is also disclosed.

Abstract: In a method for administering systemically active agents including therapeutic agents through the skin or other body membranes of humans and animals typically in the form of a transdermal device or formulation, the improvement comprising the use therewith of an effective amount of a membrane penetration enhancer having the structural formula. ##STR1## wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17.

Abstract: A novel compound bis-(N,N-dimethyl-N-carbodecyloxymethyl-N-ethyleneammonium)-sulphide dichloride of the formula ##STR1## A method for preparing said novel compound comprising quaternization of bis-(.beta.-dimethylaminoethyl)-sulphide with monochloroacetic acid decyl ester, molar ratio of said reagents being not more than 1:2.A chemotherapeutic antimicrobial preparation comprising said novel compound as an active principle in combination with a pharmaceutical carrier.A plant growth regulator in the form of an aqueous solution of said novel compound in a concentration of from 0.0001 to 0.1 wt. %.

Abstract: The disclosure describes a method for improved plant pest control comprising contacting a plant or plant pest with a composition comprising an effective amount of a plant pesticide and an effective delivery enhancing amount of compound having the structural formula ##STR1## wherein R' is H or a lower alkyl group having 1-4 carbon atoms, m is 3-7, n is 0-17 and R is --CH.sub.3, ##STR2## where R" is H or halogen, with the proviso that if m is 3 and R is CH.sub.3, then n is 5-17.Typical plant pesticides include insecticides, fungicides, herbicides, rodenticides, nematicides molluscicides and acaricides. The preferred penetration enhancing compound is 1-n-dodecylaza cycloheptan-2-one.